关键词: 舒格利单抗, 注射液, 动眼神经麻痹, 免疫检查点抑制剂, 药品不良反应, 肺腺癌

Abstract: Objective To investigate one case of oculomotor paralysis caused by immune checkpoint inhibitor-sugemalimab injection-in order to provide a reference for clinical safety and monitoring of adverse drug reactions. Methods One case of oculomotor paralysis induced by sugemalimab in a female patient with non-small cell lung cancer was analyzed. The correlations between oculomotor paralysis and sugemalimab injection were studied based on a literature review in order to find potential causes. Results Twenty-nine days after the use of pemetrexed disodium and carboplatin combined with sugemalimab injection, the patient developed blurred vision, double vision and photopsia, manifesting as oculomotor paralysis with extraocular muscle paralysis. The sugemalimab injection was discontinued and replaced by methylprednisolone and B-vitamins. Two weeks after treatment, the patient’s symptoms of oculomotor paralysis were relieved. Conclusion Oculomotor paralysis associated with sugemalimab injection can affect the quality of life of patients, which deserves more attention in clinical use.

Key words: Sugemalimab, Injection, Oculomotor Paralysis, Immune Checkpoint Inhibitors, Adverse Drug Reaction, Lung Adenocarcinoma